stella
beta
A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus — Stella
Recruiting
Back to Refractory Systemic Lupus Erythematosus trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(2 sites)
China
Research Site, Shanghai
Research Site, Wuhan
View full record on ClinicalTrials.gov